Skip to main content

Table 2 Adjusted odds ratios for receipt of concurrent CRT versus any other treatment a

From: Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer

Characteristic Estimate 95% Confidence Limits
Patient-related Lower Upper
 Female 0.64 0.40 1.03
White 1.24 1.004 1.53
 Hispanic 0.71 0.39 1.31
 Married 1.13 0.96 1.33
 Medicare enrollment any time between 2013 and 2017 1.13 0.89 1.43
 Medicaid-eligible 0.63 0.34 1.14
Priority status (reference: non-service connected)
 Service connected ≥50% 1.12 0.94 1.33
 Service connected < 50% 1.01 0.81 1.27
Urban residence 1.09 0.91 1.33
Histology (reference: squamous)
 Adenocarcinoma 0.91 0.77 1.07
 Other 0.80 0.62 1.02
Smoking status (reference: never)
 Current smoker 1.41 0.90 2.20
 Former smoker 1.34 0.85 2.10
 Unknown 1.13 0.65 1.95
Diagnosis year (reference: 2013)
2017 1.65 1.27 2.16
2016 1.36 1.06 1.76
 2015 1.11 0.88 1.39
 2014 1.22 0.98 1.53
Age (increment = 10) 0.67 0.60 0.76
Charlson-Deyo comorbidity score (increment = 1) 0.94 0.91 0.97
Distance between patient residence and medical center based on zip code (increment = 100 miles) 0.95 0.84 1.08
Medical center-related
 Geographic (Census) region (reference: South)
  Northeast 1.01 0.66 1.55
  Midwest 1.19 0.82 1.73
  West 0.89 0.60 1.33
Medical Center Certified by Commission on Cancer 0.93 0.68 1.27
Total number of unique patients seen at oncology clinics at medical center of diagnosis during diagnosis year (increment = 100) 1.03 0.92 1.15
Total number of oncologists at medical center of diagnosis (increment = 10) 0.93 0.70 1.22
  1. aFinal model based on 3093 patients who had no missing data across variables. Those from Puerto Rico were excluded due to small sample size